



MINISTERIO
DE ECONOMÍA
Y COMPETITIVIDAD

isciii
Instituto
de Salud
Carlos III

*Conferencia Salut Horizon 2020
Programa de Treball 2016-2017*

**Horizon 2020
Reto Social 1: Salud, Cambio Demográfico y
Bienestar**

**Teresa Corral
Oficina Proyectos Europeos, ISCIII
Palma de Mallorca, 15 octubre 2015**

Contenido


- Horizon 2020
- Reto Social 1: Salud, cambio demográfico y bienestar
 - Programa de trabajo
 - *Topics*
- Otras oportunidades

Programas Marco

Budget Evolution

Principal instrumento de financiación de la UE para implementar la estrategia y políticas Europeas, apoyando las actividades de Investigación, Desarrollo e Innovación Tecnológica (I+D+i)

Budget Evolution for RDI Programmes, 1984-2020 (Billion €)



Horizon 2020

Programa internacional en **competitividad, investigación cooperativa e innovación** para el periodo 2014-2020.



Ciencia excelente

Reforzar y ampliar la excelencia de la base científica de la Unión, así como a consolidar el Espacio Europeo de Investigación

Liderazgo industrial

Acelerar el desarrollo de las tecnologías e innovaciones que sustentarán las empresas del mañana

Retos sociales

Estimular la masa crítica de esfuerzos de investigación e innovación necesaria para alcanzar los objetivos políticos de la Unión

Tres pilares




Cómo Participar

Se financian actividades en todas las fases del proceso que lleva de la investigación al mercado, también actividades horizontales de apoyo a la investigación y la innovación

Tipos de acción: las actividades financiadas pueden desarrollarse según distintos tipos de acción, que llevan asociados tipos de financiación específicos

1. Acciones de Investigación e Innovación
2. Acciones de Innovación y Fast track to Innovation
3. Acciones de Coordinación y apoyo
4. Premios
5. Acciones Marie Skłodowska-Curie
6. Subvenciones del ERC
7. Acciones de Cofinanciación- COFUND
8. Instrumento PYME

H2020



Contenido

- Reto Social 1: Salud, cambio demográfico y bienestar
 - Programa de trabajo
 - *Topics*

Reto Social 1: Salud, Cambio Demográfico y Bienestar



Ageing population

Understanding disease
– personalised medicine

Chronic and infectious
disease burden

Drug development

El Programa de Trabajo 2014-2015: ¡Aún abierto!

HORIZON PRIZE:



HORIZON PRIZE - FOOD SCANNER

- HOA 7 – 2015: eHealth Inducement Prize: Food scanner

Cierra: 09-03-2016

HORIZON PRIZE - BETTER USE OF ANTIBIOTICS

- HOA 8 – 2015: Inducement Prize: An innovative test to reduce the use of antibiotics in the management of upper respiratory tract infection

Cierra: 17-08-2016

El Programa de Trabajo 2014-2015: Aún abierto

HORIZON PRIZE - BETTER USE OF ANTIBIOTICS

EXPECTED IMPACT:



Development of a rapid point-of-care test that will reduce the use of antibiotics in a safe way in patients with upper respiratory tract infections.

In this context "Upper Respiratory Tract Infections" include pharyngitis, sinusitis, otitis as well as bronchitis.

El Programa de Trabajo 2014-2015: Aún abierto

HORIZON PRIZE - FOOD SCANNER

- HOA 7 – 2015: eHealth Inducement Prize: Food scanner

The **Horizon Prize for a food scanner** will be awarded to a mobile solution that analyses precisely, quickly and efficiently food composition, nutrition facts and potentially harmful ingredients such as allergens. It should also be able to provide feedback to users regarding their health and lifestyle.



El Programa de Trabajo 2016-2017: Prioridades

Medicina personalizada, enfermedades raras, biomonitorización humana, salud mental, investigación en efectividad comparada, tecnologías avanzadas, e Health (salud electrónica) y mHealth (salud móvil) robótica, responsabilización/capacitación del paciente, envejecimiento activo y saludable, big data, valorización, resistencia a anti-microbianos, enfermedades infecciosas incluidas vacunas, salud materno-infantil y economía de los seniors

Programa Trabajo 2016-2017



EN

Horizon 2020

Work Programme 2016 - 2017

8. Health, demographic change and well-being

Important notice on the second Horizon 2020 Work Programme

This Work Programme covers 2016 and 2017. The parts of the Work Programme that relate to 2017 are provided at this stage on an indicative basis. Such Work Programme parts will be decided during 2016.

(European Commission Decision C (2015)6776 of 13 October 2015)

El Programa de Trabajo 2016-2017: Estructura

2 bloques principales:

- 1. Personalized Medicine (PM):** 21 topics organizados en 6 áreas
- 2. Coordination activities (HCO):** 15 topics
 - **Fast Track to Innovation Pilot**
 - **SME instrument:** 2 topics
 - **Other actions** (no sujeto a convocatoria, topics adicionales en apoyo a la implementación del Reto Social) 12 topics



Programa de Trabajo: Topic

Como abordar el análisis del topic

SC1-PM-09-2016: New therapies for chronic diseases

Specific Challenge: Chronic diseases represent a significant burden on individuals and healthcare systems in the European Union and beyond. Innovative and effective therapeutic approaches are required to provide the best quality of care when prevention strategies fail. While considerable basic knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.

Scope: Proposals should focus on clinical trial(s), supporting proof of concept of clinical safety and efficacy in humans of novel therapies (pharmacological as well as non-pharmacological) or the optimisation of available therapies (e.g. repurposing) for chronic non-communicable or chronic infectious diseases. Preclinical research should be completed before the start of the project. Proposals should provide a sound feasibility assessment, justified by available primary results. Gender and age must be considered whenever relevant and take their views into account. Rare diseases and regenerative medicine are not within the scope of this call. Proposals should also include a contribution from the EU of between EUR 4 and 6 million would be addressed appropriately. selection of proposals requesting other amounts.



Expected Impact:

- New or optimised therapies for men, women, children and the elderly, with the highest potential to generate advances in clinical practice and care for chronic non-communicable or chronic infectious diseases.
- Improve the therapeutic outcome of major chronic health issues with significant impact on disease burden of individual patients and health care systems.

Type of Action: Research and Innovation action

The conditions related to this topic are provided at the end of this call and in the

Programa de Trabajo 2016-2017

Call - Personalised Medicine

1.1 Understanding health, well-being and disease

- **SC1-PM-01-2016**: Multi omics for personalised therapies addressing diseases of the immune system
- SC1-PM-02-2017: New concepts in patient stratification
- SC1-PM-03-2017: Diagnostic characterisation of rare diseases
- **SC1-PM-04-2016**: Networking and optimising the use of population and patient cohorts at EU level



1.2 Preventing disease

- **SC1-PM-05-2016:** The European Human [Biomonitoring](#) Initiative
- **SC1-PM-06-2016:** [Vaccine](#) development for malaria and/or [neglected infectious](#) diseases
- SC1-PM-07-2017: Promoting [mental health](#) and well-being in the [young](#)



Programa de Trabajo 2016-2017

1.3 Treating and managing diseases

- SC1-PM-08-2017: New therapies for rare diseases
- **SC1-PM-09-2016**: New therapies for chronic diseases
- SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population
- **SC1-PM-11-2016-2017**: Clinical research on regenerative medicine



Programa de Trabajo 2016-2017

1.4 Active ageing and self-management of health

- **SC1-PM-12-2016:** PCP - eHealth innovation in empowering the patient
- **SC1-PM-13-2016:** PPI for deployment and scaling up of ICT solutions for active and healthy ageing
- **SC1-PM-14-2016:** EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities
- SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age



Programa de Trabajo 2016-2017

1.5 Methods and data

- SC1-PM-16-2017: **In-silico trials** for developing and assessing biomedical products
- SC1-PM-17-2017: **Personalised computer models** and in-silico systems for well-being
- SC1-PM-18-2016: **Big Data** supporting **Public Health policies**
- **SC1-PM-19-2017: PPI** for uptake of standards for the exchange of digitalised healthcare records
- SC1-PM-20-2017: Development of new methods and measures for improved **economic evaluation and efficiency measures** in the health sector



Programa de Trabajo 2016-2017

1.6 Health care provision and integrated care

- SC1-PM-21-2016: Implementation research for **scaling-up of evidence based innovations** and good practice in Europe and **low- and middle-income countries**



Programa de Trabajo 2016-2017

Coordination activities

- **SC1-HCO-01-2016:** Valorisation of FP7 Health and H2020 SC1 research results
- **SC1-HCO-02-2016:** Standardisation of pre-analytical and analytical procedures for *in vitro* diagnostics in personalised medicine
- SC1-HCO-03-2017: Implementing the Strategic Research Agenda on Personalised Medicine
- **SC1-HCO-04-2016:** Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance
- **SC1-HCO-05-2016:** Coordinating personalised medicine research
- **SC1-HCO-06-2016:** Towards an ERA-NET for building sustainable and resilient health system models
- SC1-HCO-07-2017: Global Alliance for Chronic Diseases (GACD)
- SC1-HCO-08-2017: Actions to bridge the divide in European health research and innovation

Programa de Trabajo 2016-2017

- **SC1-HCO-10-2016:** Support for Europe's leading Health ICT SMEs
- **SC1-HCO-11-2016:** Coordinated action to support the recognition of Silver Economy opportunities arising from demographic change
- **SC1-HCO-12-2016:** Digital health literacy
- **SC1-HCO-13-2016:** Healthcare workforce IT skills
- **SC1-HCO-14-2016:** EU-US interoperability roadmap
- **SC1-HCO-15-2016:** EU eHealth Interoperability conformity assessment
- **SC1-HCO-16-2016:** Standardisation needs in the field of ICT for Active and Healthy Ageing

Programa de Trabajo 2016-2017

Other Actions:

1. Subscription fee: Human Frontier Science Programme Organisation
2. **InnovFin Infectious Diseases (InnovFin ID) Pilot**
3. First interim evaluation of the EDCTP2 programme
4. First interim evaluation of the IMI2 programme
5. European registry for human embryonic stem cell lines
6. Studies, activities of the Scientific Panel for Health, and for conferences, events and outreach activities
7. External expertise
8. **Horizon Price on reducing maternal and new-born morbidity and mortality – the Birth Day Prize**
9. Grant to the Global Alliance for Chronic Diseases
10. Expert group for alternatives to animal testing
11. Presidency events – eHealth
12. Establishing EU mHealth hub including evidence for the integration of mHealth in the healthcare systems

InnovFin Infectious Diseases



What is InnovFin Infectious Diseases?

InnovFin Infectious Diseases enables the EIB to provide between **EUR 7.5m and EUR 75m** to innovative players active in developing vaccines, drugs, medical and diagnostic devices, and research infrastructures for combatting infectious diseases. Financing is aimed at projects that have passed the pre-clinical stage and for which clinical validation is needed for further development.

InnovFin – EU Finance for Innovators is a joint initiative by the EIB Group and the European Commission under Horizon 2020, the EU framework for research and innovation ("R&I") 2014-2020. InnovFin builds on the success of the Risk-Sharing Finance Facility developed under the seventh EU framework for research and technological development (FP7), which for the period 2007-2013 financed 114 R&I projects of EUR 11.3bn and provided loan guarantees for another EUR 1.4bn.

Indicative Term Sheet

Instrument	broad range of products ranging from standard debt instruments (i.e. senior, subordinated, and mezzanine) to risk sharing instruments (RSL)
Loan size	min EUR 7.5m – max EUR 75m
Tenor	up to 7 years
Covenants & security	project specific
Jurisdiction	laws of England and Wales
Application & inquiries	directly with the EIB (innovfinIDFF@eib.org)

Premio “Birth Day Prize”

- Aproximadamente 300,000 mujeres murieron en 2013 por causas prevenibles relacionadas con el embarazo y el parto
- Las enfermedades maternas o perinatales ocupan el séptimo lugar en la carga global de enfermedad



Otras Acciones: Premio Horizonte para la reducción de la morbi-mortalidad materna y neonatal- el Birth Day Prize

- El premio convoca a soluciones innovadoras para mejorar el desenlace en instalaciones de partos (bien sean clínicas, tecnológicas , de gestión, o una combinación de las mismas)
- Desarrollado por la Comisión Europea y la Fundación Bill & Melinda Gates
- Lanzamiento en la conferencia "Together for the next generation" el 8 de diciembre en Bruselas

Programa de Trabajo 2016-2017

Fast Track to Innovation Pilot

- Fully bottom-up
 - Consortial approach
 - Not SME related
 - Obligatory to be on market after 3 years
 - No coaching support
 - One-stage scheme
 - Industry involvement: is mandatory!
- either 2 out of 3/4 partners = private-for-profit*
• or 3 out of 5 partners = private-for-profit
• or 60% of the budget of the proposal (=total estimated eligible costs) is to be allocated to private-for-profit entities
- ✓ Restricted to MS and AC
 - ✓ 70% funding rate
 - ✓ 50 to 70 actions
 - ✓ Budget of EUR 100 million



Fast Track to Innovation Pilot

THE ULTIMATE BOOST FOR OUTSTANDING BUSINESS INNOVATORS WITH A NEED FOR SPEED...

PREPARE YOUR PROPOSAL

Build your industry-intensive consortium*
minimum 3 partners - maximum 5 partners
(all based in the EU and / or in Horizon 2020
associated countries)

DEVELOP YOUR INNOVATION

Receive an EU grant of EUR 1 million to 3 million
(70% of funding, 100% of funding for non-profit entities)

HIT THE MARKET!

Start your commercial activities



The Market
Market-Maturity to Market
Launch

Proposal



From Mature R&D
Demonstration
Market-Oriented
R&D
to Market-Mature Innovation



Market-ready result
(finished product, service,
process/ TRL 9)



Outstanding Business Innovation Concept
(high-readiness level / TRL 6, meaning
demonstrated in a relevant environment)

Continuous open call
until end 2016

6 months time-to-grant

12-24 months for implementation

At most 36 months from grant to market

*In a consortium with 3 or 4 partners, at least 2
should be industry, and in a consortium with 5
partners, at least 3; alternatively at least 60% of
the project budget should be allocated to industry
(i.e. private for profit entities)

... AND EAGER TO COMPETE ON GLOBAL MARKETS...!

ACTIVITIES SUPPORTED

Systems validation in real working conditions – Testing – Piloting – Business model validation – Standard setting – Pre-normative research – EU quality label



Programa de Trabajo 2016-2017: Borrador

Fast Track to Innovation Pilot

- Opening 2 Dec 2015
- Deadlines:
 - 15 March 2016
 - 1 June 2016
 - 25 October 2016

17.30 milion € for SC1

Programa de Trabajo 2016-2017


SME instrument

- **SMEInst-05-2016-2017** - Supporting innovative SMEs in the healthcare biotechnology sector
 - a) Cell technologies in medical applications (fase 1 y fase 2 - 2016 y 2017)
 - b) Clinical research for the validation of biomarkers and/or diagnostic medical devices (solo fase 2 y en 2017!)
- **SMEInst-06-2016-2017** - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (Fases 1, 2 y 3)



SME instrument: 3 phases

SME instrument in:
 • H2020: ~ €3 billion
 • SC1 Health: ~ €500 million



HORIZON 2020



Conferencia Salud Horizon 2020. Programa de Treball 2016-2017

Programa de Trabajo 2016-2017

Call - Digital Security Focus Area (SC7)

- DS-03-2016: Increasing digital security of health related data on a systemic level

Call - Internet of Things (Cross-cutting activities)

- IoT-01-2016: Large Scale Pilots:
 - Pilot 1: Smart living environments for ageing well



Calendario

Conv.	Nº de topic	Apertura	Fecha cierre
2016	SC1-PM-12 / 13 / 18 SC1-HCO-10 / 11 / 12 / 13 / 14 / 15 / 16	20.10.2015	16.02.2016
	SC1-PM-14		12.04.2016
	SC1-PM-01 / 04 / 05 / 06 / 09 / 11 / 21		13.04.2016
2017	SC1-PM-02 / 07/ 08 /10	29.07.2016	1st stage 04.10.2016
	SC1-PM-03 / 20 SC1-HCO-03 / 07 / 08		2nd stage 11.04.2017
	SC1-PM-15	20.09.2016	11.04.2017
	SC1-PM-16 / 17 / 19	08.11.2016	31.01.2017 14.03.2017

Tasas de financiación

100% costes directos, 25% costes indirectos, excepto:

- SC1-PM-13-2016, SC1-PM-19-2017
 - The funding rate for PPI actions is **limited to 35% of the total eligible costs** to leverage co-financing from the procurers in this specific case.
- SC1-PM-12-2016
 - The funding rate for PCP actions is limited to **90%** of the total eligible costs to leverage co-financing from the procurers in this specific case.

Oficina Proyectos Europeos-ISCIII

Asesores científicos

Gloria Villar

Tel.: 918222227 ; E-mail: gvillar@eu-isciii.es NCP Infraestructuras de Investigación

Juan E. Riese

Tel.: 918222181; E-mail: jriese@eu-isciii.es NCP SC1 y Experto en el CP

Teresa Corral

Tel.: 918222255; E-mail: tcorral@eu-isciii.es

Especialista en cuestiones financieras

Gonzalo Arévalo (NCP legal y financiero)

Tel.: 918222069; garevalo@eu-isciii.es NCP Cuestiones Legales y Financieras

Especialista en cuestiones legales

Lucía del Río (NCP - IDEAS)

Tel.: 918222381; E-mail: ldrio@eu-isciii.es NCP ERC

Especialista en relaciones con la CE

Marta Barrionuevo

Tel.: 918222969; E-mail: mbarrionuevo@eu-isciii.es

Especialista en convocatorias, documentación y boletín

Laura Mohedano

Tel.: 918222377; E-mail: lmohedano@isciii.es

